Icon and Nuffield Health to expand efforts to address radiation therapy gaps across England, starting with the acquisition of Cancer Centre London

This acquisition is part of a deepening strategic relationship that will, in time enable Icon and Nuffield Health to work together to deliver leading cancer care to many more patients across the UK.

All Nuffield Health employees at Cancer Centre London, are transferring to Icon ensuring continuity of top-quality care for patients. The existing cancer care consultants will continue to practice out of CCL and complement Nuffield Health’s existing cancer care surgical services at its nearby Parkside hospital.

Icon Group CEO, Mark Middleton OAM said the acquisition reflects a confidence in the partnership; “This acquisition is a direct result of Icon’s proven ability to partner and enhance cancer care services alongside local insights and experienced clinical teams.

“Combining Nuffield Health’s deep healthcare experience and pathways with Icon’s specialist capability in cancer treatment, increases patient access to world-class care at a critical time in the UK. Together we’re identifying areas in England where we can address the underutilisation of radiation therapy with an aim to reduce wait times and deliver integrated cancer care alongside Nuffield Health’s existing day oncology services. We hope to announce the first of these locations in early 2025”.

Alex Perry, Nuffield Health CEO said: “As cancer diagnoses continue to rise across the country, we are collaborating with Icon to create sector-leading cancer care pathways, ensuring the delivery of integrated cancer care alongside our existing oncology services. The Icon team has already done amazing work at CCL to deliver cutting-edge cancer treatment and an enhanced patient experience. This fantastic facility, team, and patients will be in the very best hands.

“We're also excited that our Nuffield Health Parkside hospital and CCL will continue to work in partnership to offer comprehensive cancer care - from surgery at Parkside through to treatment and ongoing wellbeing support at CCL next door. With cancer diagnoses rising across the country, we will also continue to work with Icon to further our partnership and develop sector leading opportunities and care pathways to tackle these challenges head on.”

For media inquiries contact:

Georgina Carter, Head of PR & Social Media Georgina.carter@nuffieldhealth.com 

About Nuffield Health

Nuffield Health is the UK’s largest healthcare charity and has been dedicated to building a healthier nation for over 65 years. We are now at the forefront of providing exceptional healthcare and fitness support through our network of 37 hospitals and 111 fitness and wellbeing centres.

We work together as a team to help you achieve your health and wellbeing ambitions, championing free health and wellbeing programmes in local communities by giving more people the tools they need to live a healthy life. These programmes help people understand and improve their own health, from those living with joint pain, to helping rehabilitate people experiencing the long-term effects from COVID-19.

Find out more about us and our pioneering models of care: https://www.nuffieldhealth.com or follow us on Facebook, Instagram and LinkedIn.

About Icon Group 

Icon Group is a global integrated provider of cancer care with significant reach across Australia, New Zealand, Asia and the United Kingdom.

Icon is built on a strong but simple mission – to deliver the best care possible to as many people as possible, as close to home as possible. The Group brings together all aspects of quality cancer care including medical oncology, haematology, radiation oncology, research, theranostics, pharmacy and compounding to deliver a truly integrated, end-to-end seamless service for cancer patients. With more than 3,500 team members, a network of more than 350 doctors, over 50 cancer centres, six compounding facilities and operational support of 70+ pharmacies, Icon is delivering world-leading care and helping address the global cancer burden.

For more information visit http://www.icongroup.global and follow Icon Group on LinkedIn

Last updated Monday 9 December 2024

First published on Monday 9 December 2024